Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo controlled rial of EGRIFTA in non-HIV patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatoheptitis (NASH)

Trial Profile

A double-blind, placebo controlled rial of EGRIFTA in non-HIV patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatoheptitis (NASH)

Planning
Phase of Trial: Phase II

Latest Information Update: 18 May 2018

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2018 New trial record
    • 11 May 2018 According to a THeratechnologies media release, the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) in the United States has awarded a grant to the Massachusetts General Hospital to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top